{
    "clinical_study": {
        "@rank": "21859", 
        "arm_group": [
            {
                "arm_group_label": "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "PT008 administered as 2 inhalations BID"
            }, 
            {
                "arm_group_label": "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "PT008 administered as 2 inhalations BID"
            }, 
            {
                "arm_group_label": "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "PT008 administered as 2 inhalations BID"
            }, 
            {
                "arm_group_label": "Budesonide Inhalation Aerosol (PT008) Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "PT008 administered as 2 inhalations BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo MID administered as 2 inhalations BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, chronic dosing (4 weeks), four-period, five-treatment,\n      incomplete block, cross-over, multicenter study to assess the efficacy and safety of four\n      doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult\n      subjects with mild to moderate persistent asthma."
        }, 
        "brief_title": "Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 - 65 years of age\n\n          -  Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to\n             screening\n\n          -  Currently receiving treatment with a low to medium dose of an ICS OR a combination of\n             controller medications for at least 4 weeks preceding screening\n\n          -  Pre-albuterol FEV1 of > 60% and < 85% of predicted normal value\n\n          -  Reversibility: Increase in FEV1 of \u2265 12% and \u2265 200mL over the pre-albuterol FEV1\n             within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin HFA\n\n          -  Asthma Symptom Criteria: Have required albuterol use on at least two of the last\n             seven days and have an Asthma Control Questionnaire (ACQ) total score \u2265 1.5 prior to\n             Randomization\n\n        Exclusion Criteria:\n\n          -  Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a\n             history of significant asthma episode(s) requiring intubation associated with\n             hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal\n             episode(s) within the 12 months prior to screening\n\n          -  Worsening of Asthma: A subject must not have experienced a worsening of asthma which\n             involved an emergency department visit, hospitalization or use of oral/parenteral\n             corticosteroids within 6 weeks of screening\n\n          -  Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only\n             intermittent, seasonal or exercise-induced asthma are excluded from participation in\n             this study\n\n          -  Concurrent Respiratory Disease\n\n          -  Pregnant women or nursing mothers\n\n          -  A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD\n\n          -  Current smokers or subjects with a > 10 pack year history of cigarettes, cigars, or\n             pipe smoking\n\n          -  Respiratory tract infection within 6 weeks prior to Visit 1\n\n          -  Subjects with documented myocardial infarction within a year from screening visit\n\n          -  Clinically significant abnormal ECG\n\n          -  Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine\n             aminotransferace (ALT), alkaline phosphatase or total bilirubin \u2265 1.5 times upper\n             limit of normal on repeat testing\n\n          -  Subjects who have cancer that has not been in complete remission for at least 5 years\n\n          -  Drug Allergy: Subjects who have a history of hypersensitivity to any component of the\n             MDI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105012", 
            "org_study_id": "PT008001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 4", 
                    "Placebo"
                ], 
                "description": "Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID", 
                "intervention_name": "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 4", 
                    "Placebo"
                ], 
                "description": "Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID", 
                "intervention_name": "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 4", 
                    "Placebo"
                ], 
                "description": "Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID", 
                "intervention_name": "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                    "Placebo"
                ], 
                "description": "Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID", 
                "intervention_name": "Budesonide Inhalation Aerosol (PT008) Dose 4", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Budesonide Inhalation Aerosol (PT008) Dose 1", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 2", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 3", 
                    "Budesonide Inhalation Aerosol (PT008) Dose 4"
                ], 
                "description": "Placebo MDI administered as 2 inhalations BID", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Mild", 
            "moderate persistent", 
            "Adult"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Pearl Therapeutics"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rolling Hills Estates", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockton", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Dartmouth", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Skillman", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sylvania", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Oswego", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medford", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma", 
        "other_outcome": [
            {
                "measure": "Change from baseline in morning pre-dose trough FEV1 over the Treatment Period and at Day 15 and Day 29 of the Treatment Period", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in mean morning and evening pre- and post-dose daily PEFR", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in the mean number of puffs of rescue Ventolin HFA", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Percentage of days without rescue Ventolin HFA use", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in pre-dose trough forced vital capacity (FVC)", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in pre-dose trough PEFR", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in pre-dose trough forced expiratory flow 25-75% (FEF25-75)", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in the number of nighttime awakenings due to asthma symptoms", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Percentage of nights with awakenings due to asthma symptoms", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Safety assessments include ECGs, vital sign measurements, clinical laboratory tests, monitoring for paradoxical bronchospasm, physical examination findings, Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }
        ], 
        "overall_contact": {
            "email": "lfaria@pearltherapeutics.com", 
            "last_name": "Lori Faria", 
            "phone": "862-777-8047"
        }, 
        "overall_official": {
            "affiliation": "Pearl Therapeutics, Inc.", 
            "last_name": "Shahid Siddiqui, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in morning pre-dose trough forced expiratory volume in one second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105012"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in mean morning pre-dose and mean evening pre-dose peak flow rate (PEFR)", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in the mean number of puffs of rescue Ventolin HFA", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Change from baseline in Asthma Control Questionnaire (ACQ) score", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "source": "Pearl Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pearl Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}